Mashup Score:25
The Lancet OncologyNICE approves routine NHS use of CAR-T for diffuse large B-cell lymphoma - 4 days
Mashup Score:25
Twitter Feed: The Lancet Oncology
This interim analysis provides support for considering carfilzomib, lenalidomide, and dexamethasone therapy in patients with newly diagnosed multiple myeloma who completed any induction regimen...
-
ICYMI: Carfilzomib, lenalidomide, & dexamethasone vs lenalidomide alone as maintenance therapy after #ASCT for #MultipleMyeloma in the phase 3 ATLAS #trial https://t.co/JxusNYkfAd #mmsm - view on twitter
Mashup Score:19
The Lancet OncologyUK cancer care: a watershed moment and the need for urgent intervention - 5 days
Mashup Score:19
In November, 2022, NHS England reported the worst ever waiting times for cancer treatment (figure 1).1,2 In the past 12 months, 69 000 patients in...
-
ICYMI: In the February issue, we published an essay by @prof_price on the dire state of UK #cancer care https://t.co/TyyBhMOYMl - view on twitter
More coverage:
#cancer
Mashup Score:18
The Lancet OncologyCall to the UK Government for a radical new cancer recovery plan - 5 days
Mashup Score:18
The recent Essay by Pat Price and colleagues1 and the accompanying Comment2 in The Lancet Oncology add to what is now a clarion call...
-
and a letter from @timfarron @grahamemorris calling on the government for a new #cancer recovery plan https://t.co/29iGrga5QY - view on twitter
More coverage:
#cancer
Mashup Score:17
The Lancet OncologyFirefighters at increased risk of cancer diagnosis - 3 weeks
Mashup Score:17
Research commissioned by the UK Fire Brigades Union is currently underway at the University of Central Lancashire (UCLan, Preston, UK) into the impact of...
-
News Feature: #Firefighters at increased risk of #cancer diagnosis https://t.co/CceKFJ4kDq - view on twitter
Mashup Score:12
The Lancet OncologyThis study provides evidence that right-sided hemicolectomy is not indicated after complete resection of an appendiceal NET of 1–2 cm in size by appendectomy,...
-
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study https://t.co/3xlnqQJkIf - view on twitter
Mashup Score:7
The Lancet OncologyTattoos, inks, and cancer - 5 days
Mashup Score:7
The introduction in the dermis of exogenous pigments and dyes to obtain a permanent design (tattooing) represents a unique in-vivo situation, where a large...
-
Good question from IARC on cancer risk associated with tattoos--a question we asked 10 years ago, see here: https://t.co/CvaQDfNZfl https://t.co/CvaQDfNZfl - view on twitter
Mashup Score:7
The Lancet OncologySex disparity in childhood cancer in India: a multi-centre, individual patient data analysis - 1 month
Mashup Score:7
The sex ratio for childhood cancer in India has a bias towards boys at the level of diagnosis, which is more pronounced in northern...
-
Shocking new data exposing bias against girls receiving cancer treatment in India, in latest issue of @TheLancetOncol. See https://t.co/MafZG77tBd - view on twitter
Mashup Score:7
The Lancet OncologyNot all mutations related to TMB-H can enhance antitumour immune response. More composite biomarkers should be investigated (eg, mTMB signature) to tailor treatment with...
-
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study https://t.co/CAZ8SgaD9o - view on twitter
This interim analysis provides support for considering carfilzomib, lenalidomide, and dexamethasone therapy in patients with newly diagnosed multiple myeloma who completed any induction regimen...
-
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial https://t.co/AwQ3ypKrA6 - view on twitter
The chimeric antigen receptor T-cell (CAR-T) therapy axicabtagene ciloleucel has been approved for routine use in relapsed or refractory diffuse large B-cell lymphoma after...
News: NICE approves routine #NHS use of #CARTtherapy #axicabtageneciloleucel for diffuse large B-cell #lymphoma https://t.co/ars3n9GX26 - view on twitter